ERBB2 and breast carcinoma: From the resulting dataset, we estimated a c-Met signaling score cut-off to identify abnormal signaling patients and estimated the prevalence of HER2-negative breast cancer patients that have both hyperactive c-Met signaling and hyperactive signaling from at least one of the four HER-family receptors.